Cargando…

Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma

Doxorubicin (Dox) is one of the most important first-line drugs used in osteosarcoma therapy. Multiple and not fully clarified mechanisms, however, determine resistance to Dox. With the aim of identifying new markers associated with Dox-resistance, we found a global up-regulation of small nucleolar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godel, Martina, Morena, Deborah, Ananthanarayanan, Preeta, Buondonno, Ilaria, Ferrero, Giulio, Hattinger, Claudia M., Di Nicolantonio, Federica, Serra, Massimo, Taulli, Riccardo, Cordero, Francesca, Riganti, Chiara, Kopecka, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349977/ https://www.ncbi.nlm.nih.gov/pubmed/32599901 http://dx.doi.org/10.3390/ijms21124500

Ejemplares similares

Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
por: Hattinger, Claudia Maria, et al.
Publicado: (2023)

ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma
por: Belisario, Dimas Carolina, et al.
Publicado: (2020)

Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
por: Hattinger, Claudia Maria, et al.
Publicado: (2021)

Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
por: Serra, Massimo, et al.
Publicado: (2021)

Sound-based assembly of a microcapillary network in a saturn-like tumor model for drug testing
por: Di Marzio, Nicola, et al.
Publicado: (2022)

An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells
por: Campia, Ivana, et al.
Publicado: (2015)

PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy
por: Salaroglio, Iris C., et al.
Publicado: (2017)

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
por: Hattinger, Claudia Maria, et al.
Publicado: (2020)

SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2022)

Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer
por: Godel, Martina, et al.
Publicado: (2021)

CircNT5E/miR-422a: a new circRNA-based ceRNA network in glioblastoma
por: Morena, Deborah, et al.
Publicado: (2019)

Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells
por: Riganti, Chiara, et al.
Publicado: (2013)

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells
por: Rigoni, Micol, et al.
Publicado: (2015)

iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells
por: De Boo, Sara, et al.
Publicado: (2009)

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments
por: Fanelli, Marilù, et al.
Publicado: (2020)

Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells
por: Vella, Serena, et al.
Publicado: (2016)

Overcoming drug resistance in glioblastoma: new options in sight?
por: Kopecka, Joanna, et al.
Publicado: (2021)

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing
por: Hattinger, Claudia Maria, et al.
Publicado: (2022)

Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death
por: Kopecka, Joanna, et al.
Publicado: (2020)

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
por: Salaroglio, Iris C., et al.
Publicado: (2018)

Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy
por: Chirio, Daniela, et al.
Publicado: (2022)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

A Mouse Model of Pulmonary Metastasis from Spontaneous Osteosarcoma Monitored In Vivo by Luciferase Imaging
por: Miretti, Silvia, et al.
Publicado: (2008)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

Editorial: Novel therapeutic approaches to target drug resistant tumors
por: Riganti, Chiara, et al.
Publicado: (2023)

Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
por: Hattinger, Claudia M., et al.
Publicado: (2016)

Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?
por: Punzo, Francesca, et al.
Publicado: (2020)

The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia
por: Carrà, Giovanna, et al.
Publicado: (2016)

Future perspectives from lung cancer pre-clinical models: new treatments are coming?
por: Bersani, Francesca, et al.
Publicado: (2020)

Electronic Coupling in 1,2,3-Triazole Bridged Ferrocenes and Its Impact on Reactive Oxygen Species Generation and Deleterious Activity in Cancer Cells
por: Biegański, Przemysław, et al.
Publicado: (2022)

Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors
por: Kopecka, Joanna, et al.
Publicado: (2016)

Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression
por: Chen, Jiayi, et al.
Publicado: (2021)

Contribution of Mitochondrial Activity to Doxorubicin-Resistance in Osteosarcoma Cells
por: Giacomini, Isabella, et al.
Publicado: (2023)

Doxorubicin Dose Deintensification in Pediatric Osteosarcoma, Is Less Better?
por: Halalsheh, Hadeel, et al.
Publicado: (2023)

Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin
por: Qu, Yang, et al.
Publicado: (2022)

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
por: Duan, Zhenfeng, et al.
Publicado: (2014)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein
por: Wu, Dapeng, et al.
Publicado: (2017)

Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma
por: Ren, Xiaojun, et al.
Publicado: (2020)

Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells
por: Kazantseva, Liliya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eplcfsqm7502brn5h4knneglc2